other material
confidence high
sentiment positive
materiality 0.85
CG Oncology reports 74.5% CR rate in Phase 3 BOND-003; median DOR >27 months
CG Oncology, Inc.
- 74.5% (82/110) achieved complete response at any time (95% CI 65.4-82.4%).
- Median duration of response not reached but exceeds 27 months; 63.5% probability of response at 12 months.
- No Grade 3+ treatment-related adverse events or deaths; 97.3% completed all treatments.
- Progression-free survival at 12 months: 97.3%; no progression to muscle-invasive cancer.
- Cystectomy-free survival at 12 months: 90.0%; 50% of reinduced patients converted to CR.